SCHEMBL5211343

SCHEMBL5211343

CCONC(=O)COc1cccc2c1c1c(C(N)=O)cccc1n2Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 16/20 0.55
PLA2G10 O15496 6/20 0.53
PLA2G2E Q9NZK7 4/20 0.53
PLA2G2D Q9UNK4 4/20 0.53
PLA2G5 P39877 3/20 0.53
PLA2G2F Q9BZM2 3/20 0.53
PLA2G1B P04054 3/20 0.53
PLA2G6 O60733 1/20 0.53
PLA2G2C Q5R387 1/20 0.53
PLA2G12B Q9BX93 1/20 0.53
PLA2G12A Q9BZM1 1/20 0.53
PLA2G3 Q9NZ20 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5209619 0.91 PLA2G2A (0.52) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL5212158 0.90 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL5212737 0.90 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL6727355 0.89 PLA2G2A (0.55) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL5213070 0.88 PLA2G2A (0.53) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL5208128 0.88 PLA2G2A (0.55) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL6610906 0.86 PLA2G2A (0.52) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL817831 0.85 PLA2G2A (0.63) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL6719876 0.85 PLA2G2A (0.64) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5
SCHEMBL29862240 0.85 PLA2G2A (0.63) PLA2G2APLA2G10PLA2G2EPLA2G2DPLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395554-B1 SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 LILLY CO ELI (US) 2007-02-14 EP claimed
EP-1395554-A1 SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 ELI LILLY AND COMPANY (US) 2004-03-10 EP claimed
WO-2002079154-A1 SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 ELI LILLY AND COMPANY (US) 2002-10-10 WO claimed
EP-1395554-B1 SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 LILLY CO ELI (US) 2007-02-14 EP disclosed
US-6933313-B2 Substituted carbazoles as inhibitors of sPLA2 ELI LILLY AND COMPANY (US) 2005-08-23 US disclosed
US-20040087796-A1 Substituted carbazoles as inhibitors of spla2 HARPER RICHARD WALTZ (US) 2004-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087796-A1 Substituted carbazoles as inhibitors of spla2 HCAR2, ALOX12, SPTLC2 PLA2G2A 59/4885PLA2G10 143/4885PLA2G2E 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.